Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
COSCIENS Biopharma Inc
T.CSCI
Alternate Symbol(s):
CSCI
Healthcare
Biotechnology
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone...
deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CSCI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 27, 2024 8:57am
Perplexity Ai:
Based on the press release, it appears that the Phase 3 DETECT trial of macimorelin for diagnosing childhood-onset growth hormone deficiency (CGHD) did not meet its primary efficacy endpoint as
...more
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Comment by
prophetoffactz
on Aug 27, 2024 8:50am
RE:RE:The unexpected
Macimorelin is a key asset and could finance the path forward. Is it the asset the US knows most about and the response of the market to this news may therefore overweight its significance? What is
...more
Redefining Neuroprotection: Revive’s Approach to Treating Brain Injury from Nerve Agents
posted Dec 03, 2024 9:00am by
Revive Therapeutics Ltd
-
|
Evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The DRDC is investigating pharmacological compounds, including Bucillamine, that can mitigate nerve agent induced brain injury. ...read more
(109)
•••
fossi_2002
X
View Profile
View Bullboard History
Post by
fossi_2002
on Aug 27, 2024 8:48am
...did not meet primary endpoint
COSCIENS Biopharma -2,84 -48,46% That's the truth!!! We've all had enough of your fairy tales!
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Comment by
prophetoffactz
on Aug 27, 2024 8:43am
RE:The unexpected
The other industry tests may be worse than the industry expects and falsely classifying some subjects as growth hormone deficient? "Although further analysis of the study results is required
...more
(3)
•••
Schellaj
X
View Profile
View Bullboard History
Comment by
Schellaj
on Aug 27, 2024 8:42am
RE:The unexpected
And yet CSCI is down almost 50% on the American market this morning.
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 27, 2024 8:38am
The unexpected
1) Excellent safety was confirmed: "The top-line results confirm the excellent safety of macimorelin, similar to what was demonstrated in our clinical and commercial experience with the use of
...more
(109)
•••
fossi_2002
X
View Profile
View Bullboard History
Post by
fossi_2002
on Aug 27, 2024 8:00am
...did not meet primary endpoint
How much longer will the shareholders have to put up with this total miscast by the name of Gilles Gagnon and how much longer will we have to listen to the repetitive nonsense of Proph... .
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Aug 27, 2024 7:30am
New Press Release - COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol- Potent growth hormone release following macimorelin stimulation- Safety of macimorelin confirmed in the pediatric populationTORONTO, ONTARIO, Aug. 27, 2024 (GLOBE NEWSWIRE...
read article.
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Comment by
prophetoffactz
on Aug 27, 2024 12:54am
RE:RE:Perplexity Ai's expectations for pediatric trial results
Are these valid expectations? The pediatric trial compares macimorelin to clonidine and arginine. Here's what Perplexity Ai says including the other tests: Given this data, we can refine
...more
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Comment by
prophetoffactz
on Aug 26, 2024 11:21pm
RE:Perplexity Ai's expectations for pediatric trial results
After feeding Perplexity Ai more info about the dose finding pediatric trial this was its conclusion: This additional information provides valuable insights into the pediatric trial results for
...more
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Post by
prophetoffactz
on Aug 26, 2024 11:09pm
Perplexity Ai's expectations for pediatric trial results
I asked what sensitivity/specificity Perplexity Ai expected from the pediatric trial, how it compared to other tests, and gave it these previous pediatric results: "In all three dosing cohorts
...more
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Comment by
prophetoffactz
on Aug 26, 2024 2:39pm
RE:RE:RE:RE: Instant success
Hopeforthbest, why don't you show us any preclinical or clinical data for the avenanthramide pill? What is this fomulation they have created? Is it a slow-release formulation? How unique compared
...more
(150)
•••
Hopeforthebest
X
View Profile
View Bullboard History
Comment by
Hopeforthebest
on Aug 26, 2024 1:53pm
RE:RE:RE: Instant success
Everytime you post proph/gagnon, the banjo music is defeatening
(104)
•••
prophetoffactz
X
View Profile
View Bullboard History
Comment by
prophetoffactz
on Aug 26, 2024 1:42pm
RE:RE: Instant success
Hopeforthebest's lack of understanding of business is stunning. He has no idea what steath mode is as a company works towards key strategic milestones. As Hopeforthebest complains about
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Debt-Free Cannabis Company Set for Next Stage of Growth
Learn How this Company is Disrupting Point-of-Care Testing